Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-520, KSP inhibitor · 4 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| ARRY-520 | EXPERIMENTAL | - |
| ARRY-520 + G-CSF support | EXPERIMENTAL | - |
| ARRY-520 + dexamethasone + G-CSF support | EXPERIMENTAL | - |
| ARRY-520 (Schedule 1) + bortezomib + G-CSF | EXPERIMENTAL | - |
| ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF | EXPERIMENTAL | - |
| ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-520, KSP(Eg5) inhibitor; intravenous | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule. |
| Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous | DRUG | Part 1: standard of care; Part 2: standard of care; Part 3: standard of care. |
| Dexamethasone, steroid; oral | DRUG | Part 3: standard of care. |
| Bortezomib, proteasome inhibitor; intravenous or subcutaneous | DRUG | Part 1: standard of care; Part 2: standard of care determined in Part 1. |
Key Inclusion Criteria (Part 3): * Patients should have received at least two prior treatment regimens. * Confirmed refractory MM (measurable disease) or PCL. Patients must be refractory to treatment with both lenalidomide/dexamethasone and bortezomib/dexamethasone (or to treatment with bortezomib/...
ARRY-520 is an investigational small molecule being studied in oncology for advanced myelodysplastic syndromes (MDS), advanced solid tumors, multiple myeloma, and plasma cell leukemia. It has been evaluated in Phase 1 clinical trials in patients with these advanced or relapsed/refractory hematologic and solid tumor cancers.
ARRY-520 is a KSP inhibitor, also known as an Eg5 inhibitor. KSP (Eg5) is a kinesin spindle protein required for mitotic spindle formation and cell division. By inhibiting KSP, ARRY-520 interferes with mitosis in cancer cells. It is a small molecule administered intravenously.
ARRY-520 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The compound originated as a kinesin spindle protein (KSP/Eg5) inhibitor and is being advanced by Pfizer in oncology indications including multiple myeloma and advanced solid tumors.
ARRY-520 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program has evaluated the agent in patients with relapsed or refractory multiple myeloma, plasma cell leukemia, advanced myeloid leukemia, advanced MDS, and advanced solid tumors.
ARRY-520 has been studied in completed Phase 1 trials including NCT01248923 (with bortezomib and dexamethasone in relapsed/refractory multiple myeloma), NCT00821249 (relapsed or refractory multiple myeloma), NCT00637052 (advanced myeloid leukemia), and NCT00462358 (advanced solid tumors). All were conducted in the United States.
Yes. ARRY-520 is also known as a KSP(Eg5) inhibitor and is given intravenously. KSP, or Eg5, is a kinesin spindle protein targeted by the drug. These names refer to the same investigational small molecule compound developed by Pfizer.